

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 February 2006 (23.02.2006)

PCT

(10) International Publication Number
WO 2006/018725 A1

(51) International Patent Classification⁷: **C07D 487/04**,
405/06, 309/32, 513/04, 405/14, A61K 31/351, 31/366,
A61P 31/14

(74) Agent: RUDDOCK, Keith, S.; c/o Pfizer Research and
Development, Ramsgate Road, Kent, Sandwich CT13 9NJ
(GB).

(21) International Application Number:
PCT/IB2005/002697

(22) International Filing Date: 5 August 2005 (05.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/602,618 18 August 2004 (18.08.2004) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GONZALEZ, Javier** [US/US]; Patent Department, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **JEWELL, Tanya, Michelle** [US/US]; Patent Department, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **LI, Hui** [US/US]; Patent Department, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **LINTON, Angelica** [US/US]; Patent Department, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **TATLOCK, John, Howard** [US/US]; Patent Department, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME



(57) Abstract: The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).